- Home
- SGA vs PLRX Comparison
SGA vs PLRX Comparison
Compare SGA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- PLRX
- Stock Information
- Founded
- SGA 1986
- PLRX 2015
- Country
- SGA United States
- PLRX United States
- Employees
- SGA N/A
- PLRX N/A
- Industry
- SGA Broadcasting
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- PLRX Health Care
- Exchange
- SGA Nasdaq
- PLRX Nasdaq
- Market Cap
- SGA 78.8M
- PLRX 93.3M
- IPO Year
- SGA 1992
- PLRX 2020
- Fundamental
- Price
- SGA $11.96
- PLRX $1.61
- Analyst Decision
- SGA
- PLRX Hold
- Analyst Count
- SGA 0
- PLRX 11
- Target Price
- SGA N/A
- PLRX $3.79
- AVG Volume (30 Days)
- SGA 9.2K
- PLRX 742.3K
- Earning Date
- SGA 11-06-2025
- PLRX 11-06-2025
- Dividend Yield
- SGA 8.53%
- PLRX N/A
- EPS Growth
- SGA N/A
- PLRX N/A
- EPS
- SGA 0.05
- PLRX N/A
- Revenue
- SGA $109,822,000.00
- PLRX N/A
- Revenue This Year
- SGA N/A
- PLRX N/A
- Revenue Next Year
- SGA $5.37
- PLRX N/A
- P/E Ratio
- SGA $245.58
- PLRX N/A
- Revenue Growth
- SGA N/A
- PLRX N/A
- 52 Week Low
- SGA $10.75
- PLRX $1.10
- 52 Week High
- SGA $14.27
- PLRX $15.80
- Technical
- Relative Strength Index (RSI)
- SGA 44.82
- PLRX 48.59
- Support Level
- SGA $11.35
- PLRX $1.48
- Resistance Level
- SGA $12.07
- PLRX $1.63
- Average True Range (ATR)
- SGA 0.29
- PLRX 0.11
- MACD
- SGA -0.00
- PLRX -0.01
- Stochastic Oscillator
- SGA 49.55
- PLRX 41.10
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.